MBX Biosciences
Highly Engaged Employees
Highly Engaged EmployeesChemicals & Related Products · Indiana, United States · 51-200 Employees
View Company Info for Free
Overview
Headquarters
11711 N Meridian St Ste 300, Carmel, Ind...Phone Number
(317) 659-0200Website
www.mbxbio.comRevenue
-Stock Symbol
MBXIndustry
ZI Rank: 1
Signal Type
Mar
Apr
May
Jun
Jul
Aug
ZI Rank
1
1
1
1
1
1
About MBX Biosciences
MBX Biosciences is a biotechnology company focused on developing therapies for rare endocrine diseases. Founded in 2018, it leverages proprietary technology and drug candidates licensed from the DiMarchi Indiana University laboratory. Its leadership team brings prior experience in developing successful endocrine drugs and building biotechnology companies. Supported by leading life science investors, the company aims to advance innovative treatments to address unmet medical needs in endocrine disorders.Explore more
MBX Biosciences Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is MBX Biosciences your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Check out if MBX Biosciences is spiking on competitors!
Product Launch: Get notified when MBX Biosciences launches new products
Website visits: Recent activity has been detected on your website
Click to see if MBX Biosciences had a recent Job posting/layoffs
Check if MBX Biosciences has recently received funding, and reach out quickly before it becomes old news!
MBX Biosciences, which may be a good buyer, showed buying intent in Masked Content Topic
Funding: Get notified immidiatlly once MBX Biosciences has new funding data
Congratulate Masked Content for being promoted to Masked Content at MBX Biosciences
Earning: See what the market has to say on MBX Biosciences recently announced quarterly report
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find 2 more new buyers
Compare Similar Companies to MBX Biosciences
Compare insights from companies similar to MBX Biosciences, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
MBX Biosciences is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
MBX Biosciences is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about MBX Biosciences.
MBX Biosciences financials insights
Gather financial insights about MBX Biosciences, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2020
Series A
$34.6M
2022
Series B
$115M
2024
Series C
$63.5M
MBX Biosciences Tech Stack
A closer look at the technologies used by MBX Biosciences
See more technologies
Most Recent Scoops
Open Position
Person-Based
Stake & Stock Ownership, Finance, Financial Transactions
Open Position
Person-Based
Person-Based
MBX Biosciences News & Media
MBX Biosciences Announces Appointment of Jeff Held as Chief Legal Officer
CARMEL, Ind. and BURLINGTON, Mass., Sept. 08, 2026 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. (Nasdaq: MBX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel precision peptide therapies for the treatment of endocrine and metabolic disorders, today announced the appointment of Jeff Held, J.D., as Chief Legal Officer. Mr. Held brings more than three decades of legal, compliance and executive leadership experience across biotechnology, lMBX Biosciences Announces First Patient Dosed in Pivotal Phase 3 oPTimize Trial of Once-Weekly Canvuparatide in Adults with Hypoparathyroidism
Pivotal Phase 3 oPTimize trial design builds on positive Phase 2 Avail™ results and durable one-year clinical benefitMBX Biosciences Reports Second Quarter 2026 Financial Results and Corporate Highlights
One-year data demonstrated sustained benefit of once-weekly canvuparatide as a potential PTH replacement therapy in chronic hypoparathyroidism; Phase 3 pivotal trial now recruitingMBX Biosciences Announces Executive Leadership Transition to Support the Company’s Next Phase of Growth
CARMEL, Ind. and BURLINGTON, Mass., July 13, 2026 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. (Nasdaq: MBX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel precision peptide therapies for the treatment of endocrine and metabolic disorders, today announced that its Board of Directors has appointed Steve Hoerter, current Executive Chairman of the Board, as its new Chairman and Chief Executive Officer. Mr. Hoerter succeeds Kent Hawryluk
Read more news
Top Chemicals & Related Products Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding MBX Biosciences
Sign Up For FreeTo access detailed company insights
MBX Biosciences is a biotechnology company focused on developing therapies for rare endocrine diseases. Founded in 2018, it leverages proprietary technology and drug candidates licensed from the DiMarchi Indiana University laboratory. Its leadership team brings prior experience in developing successful endocrine drugs and building biotechnology com... Read More
